中国生物制药(01177.HK):TQ-A3334“TLR7激动剂”及TQA3605“核心蛋白变构调节剂”获CDE纳入突破性治疗药物程序

智通财经
Yesterday
【中国生物制药(01177.HK):TQ-A3334“TLR7激动剂”及TQA3605“核心蛋白变构调节剂”获CDE纳入突破性治疗药物程序】智通财经APP讯,中国生物制药(01177.HK)发布公告,本集团附属公司正大天晴药业集团股份有限公司(正大天晴)自主研发的国家1类创新药TQ-A3334“Toll样受体7(TLR7)激动剂”及TQA3605“核心蛋白变构调节剂”均已获中国国家药品监督管理局药品审评中心 (CDE)纳入突破性治疗药物程序。两款创新药分别针对慢性乙型肝炎(慢乙肝)治疗中尚未满足的两大需求,功能性治愈与低病毒血症(LLV)。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10